Journal article

The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.

Michelle J Butler, David Eccleston, David J Clark, Andrew E Ajani, Nick Andrianopoulos, Angela Brennan, Gishel New, Alexander Black, Gregory Szto, Chris M Reid, Bryan P Yan, James A Shaw, Anthony M Dart, Stephen J Duffy, undefined Melbourne Interventional Group

Am Heart J | Published : 2009


BACKGROUND: The optimal duration of clopidogrel use for prevention of stent thrombosis with drug-eluting stent (DES) use is uncertain. Our objective was to determine whether the planned duration of clopidogrel at the time of percutaneous coronary intervention affected patient outcomes. METHODS: We analyzed data from 2,980 patients who underwent percutaneous coronary intervention in the Melbourne Interventional Group registry who had 12-month follow-up. We compared outcomes at 30 days and 12 months according to planned duration of clopidogrel use. RESULTS: Twelve-month mortality was significantly lower in patients with a DES with a longer (>or=12 months) planned duration of clopidogrel when c..

View full abstract

University of Melbourne Researchers